Dr Erick G Martell, MD | |
1919 Lathrop St, Fairbanks, AK 99701-5937 | |
(907) 459-3586 | |
(907) 374-7770 |
Full Name | Dr Erick G Martell |
---|---|
Gender | Male |
Speciality | Plastic And Reconstructive Surgery |
Experience | 24 Years |
Location | 1919 Lathrop St, Fairbanks, Alaska |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1649303694 | NPI | - | NPPES |
1720992 | Medicaid | AK |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | 11981 (Hawaii) | Secondary |
208200000X | Plastic Surgery | 168881 (Alaska) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Fairbanks Memorial Hospital | Fairbanks, AK | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
North Star Plastic Surgery Llc | 2860849478 | 2 |
News Archive
Karolinska Development: Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT. The data show that SHACT is effective in reducing pain in connection with intrauterine device insertion. Karolinska Development owns 63% of Pharmanest.
Scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, with collaborators from Harvard University, the University of Madrid, Princeton University, and the University of Zurich, have discovered a new mechanism that may alter principle understandings of molecular interactions within a cell's nucleus.
BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.
Researchers study human single nucleotide variants (SNVs) using machine learning to identify amino acid changes that alter kinase-bound sequence motifs.
› Verified 2 days ago
Entity Name | North Star Plastic Surgery Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1417653569 PECOS PAC ID: 2860849478 Enrollment ID: O20231103000373 |
News Archive
Karolinska Development: Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT. The data show that SHACT is effective in reducing pain in connection with intrauterine device insertion. Karolinska Development owns 63% of Pharmanest.
Scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, with collaborators from Harvard University, the University of Madrid, Princeton University, and the University of Zurich, have discovered a new mechanism that may alter principle understandings of molecular interactions within a cell's nucleus.
BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.
Researchers study human single nucleotide variants (SNVs) using machine learning to identify amino acid changes that alter kinase-bound sequence motifs.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Erick G Martell, MD Po Box 73720, Fairbanks, AK 99707-3720 Ph: (305) 761-1934 | Dr Erick G Martell, MD 1919 Lathrop St, Fairbanks, AK 99701-5937 Ph: (907) 459-3586 |
News Archive
Karolinska Development: Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT. The data show that SHACT is effective in reducing pain in connection with intrauterine device insertion. Karolinska Development owns 63% of Pharmanest.
Scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, with collaborators from Harvard University, the University of Madrid, Princeton University, and the University of Zurich, have discovered a new mechanism that may alter principle understandings of molecular interactions within a cell's nucleus.
BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.
Researchers study human single nucleotide variants (SNVs) using machine learning to identify amino acid changes that alter kinase-bound sequence motifs.
› Verified 2 days ago